A tumor sample obtained using only a single biopsy may not necessarily reflect the dominant properties of the tumor, and the primary activating EGFR mutation appears to represent the non-dominant tumor clone in patients with EGFR-TKI-resistant NSCLC. The gene discussed is EGFR; the disease is neoplasm.